Key result
Worsening renal function at 3-6 months after TAVR in patients with baseline renal dysfunction was associated with an increased risk of mortality (HR 2.2; 95% CI 1.17-4.27; p=0.015).
Why the study?
CKD, AKI, and worsening renal function at 30 days after TAVR portend poor outcomes, but the association between worsening renal function at 3-6 months and mortality in patients with baseline renal dysfunction remained to be evaluated.
Does mid-term worsening renal function post-TAVR increase mortality in patients with baseline chronic kidney disease?
Cohort (n=176)
No
Does mid-term worsening renal function post-TAVR increase mortality in patients with baseline chronic kidney disease?
Hazard Ratio: 2.2 (95% CI 1.17–4.27)
p-value: p=0.015
Mid-term worsening renal function after TAVR in patients with baseline chronic kidney disease is associated with a more than twofold increased risk of mortality.
Worsening renal function at 3-6 months may signal higher mortality after TAVR in CKD; hypothesis-generating, prospective studies needed before practice change.
INTRODUCTION: Chronic kidney disease (CKD), acute kidney injury (AKI) and worsening renal function at 30 days after transcatheter aortic valve replacement (TAVR) portend poor outcomes. We sought to evaluate the association between worsening renal function at 3-6 months and mortality among patients with baseline renal dysfunction undergoing TAVR. METHODS: This is a retrospective study of patients with glomerular filtration rate (GFR) < 60 ml/min undergoing TAVR between June 2011 and March 2019 at the Regional Cardiac Catheterization Lab at Kaiser Permanente Los Angeles. Worsening renal function at 3-6 months post-TAVR was defined as: increase in serum creatinine >1.5 times compared to baseline, absolute increase of ≥0.3 mg/dl, or initiation of dialysis. RESULTS: Of 683 patients reviewed, 176 were included in the analysis (median age 84 [IQR 79-88] years, 56% female). Of these, 27 (15.3%) had worsening renal function. AKI post-TAVR (OR 2.9, 95% CI 1.1-7.4, p = .03) and transfusion of ≥4 units red blood cells (OR 8.4, 95% CI 1.2-59, p = .03) were independent predictors of worsening renal function. Worsening renal function increased risk for mortality (HR 2.2, 95% CI 1.17-4.27, p = .015) at a median follow-up of 691 days. Those with improved/stable function with baseline GFR < 60 ml/min had comparable mortality risk to those with baseline GFR ≥ 60 ml/min (18% vs. 16.5%; HR 1.1, 95% CI 0.72-1.75, p = .62). CONCLUSION: Among patients with baseline renal dysfunction, only 15% developed worsening renal function at 3-6 months after TAVR, which was associated with increased mortality. Predictors for worsening renal function include AKI and blood transfusions. Preventative measures peri-procedurally and continued monitoring post-discharge are warranted to improve outcomes.
No takes yet. Share an insight, caveat, or question.
Phan et al. (2020) conducted a cohort in Baseline renal dysfunction undergoing transcatheter aortic valve replacement (TAVR) (n=176). Worsening renal function at 3-6 months post-TAVR vs. Improved or stable renal function was evaluated on Mortality (HR 2.2, 95% CI 1.17-4.27, p=0.015). Worsening renal function at 3-6 months after TAVR in patients with baseline renal dysfunction was associated with an increased risk of mortality (HR 2.2; 95% CI 1.17-4.27; p=0.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: